Overview of Klor-Con M20
Klor-Con M20 is an extended-release oral dosage form of potassium chloride, containing 1500 mg of microencapsulated potassium chloride, equivalent to 20 mEq of potassium per tablet. It is designed to slow the release of potassium, reducing the risk of high localized concentrations within the gastrointestinal tract[1].
Market Context
The market for potassium chloride supplements is competitive, with multiple products available. Klor-Con M20 competes directly with other extended-release potassium chloride products, such as Schering's K-Dur 20. The market includes over 20 different potassium chloride supplements, all vying for market share[2].
Historical Sales and Market Performance
Historically, the launch of Klor-Con M20 was significant due to its impact on the market dominated by Schering's K-Dur 20. When Upsher-Smith launched Klor-Con M20 in September 2001, following a settlement with Schering, it entered a market where K-Dur 20 had been the leading product. Schering's K-Dur 20 had sales of $290 million in 2000, with the vast majority of those sales occurring in the U.S.[2].
Pricing and Cost
The pricing of Klor-Con M20 is competitive, with a cost of around $28 for a supply of 90 tablets for cash-paying customers. Generic versions of potassium chloride are also available, further influencing pricing dynamics. For example, a generic version of potassium chloride can cost as low as $30.05 for 100 tablets[4].
Sales Projections
Current Market Trends
Given the competitive nature of the market, sales projections for Klor-Con M20 must consider the overall demand for potassium chloride supplements and the competitive landscape. The drug's extended-release formulation and microencapsulated design provide a unique selling point, potentially attracting patients and healthcare providers looking for a reliable and safe potassium supplement[1].
Market Share
Klor-Con M20 has established itself as a significant player in the market. Since its launch, it has been shipped to all major wholesalers and is widely available in the U.S. market. The product's market share is influenced by its competitive pricing, the availability of generic alternatives, and the marketing efforts of its manufacturer, Upsher-Smith[2].
Future Outlook
The future outlook for Klor-Con M20 is positive, given the ongoing demand for potassium chloride supplements. Here are a few key factors that will influence its sales projections:
- Demand for Hypokalemia Treatment: The need for potassium supplements to treat and prevent hypokalemia remains steady, ensuring a consistent demand for products like Klor-Con M20.
- Competitive Pricing: The availability of generic versions and competitive pricing strategies will continue to play a crucial role in market share.
- Regulatory Environment: Changes in regulatory policies or the approval of new formulations could impact the market dynamics.
Statistical Insights
- Sales Volume: Historical data indicates that Klor-Con M20 has been successful in capturing a significant portion of the market. For instance, after its launch, Upsher-Smith began shipping the product to all major wholesalers, indicating strong initial sales[2].
- Price Sensitivity: The price range for Klor-Con M20 and its generic counterparts suggests that consumers are price-sensitive. Therefore, maintaining competitive pricing is crucial for sales projections[4].
Key Challenges and Opportunities
Challenges
- Competition: The presence of multiple potassium chloride supplements, including generic versions, poses a significant challenge.
- Regulatory Risks: Any changes in FDA regulations or patent disputes could impact the product's market position[2].
Opportunities
- Expanding Patient Base: Increasing awareness about the importance of potassium supplementation could expand the patient base.
- Innovative Marketing: Effective marketing strategies and partnerships with healthcare providers can enhance market share.
Expert Insights
Industry experts emphasize the importance of comparative added clinical benefit in driving market performance. While Klor-Con M20 does not have the same level of clinical benefit as some newer drugs in other therapeutic areas, its established safety profile and extended-release formulation provide significant value to patients and healthcare providers[3].
Key Takeaways
- Competitive Market: Klor-Con M20 operates in a highly competitive market with multiple potassium chloride supplements.
- Pricing Strategy: Competitive pricing is crucial for maintaining market share.
- Demand Stability: The demand for potassium chloride supplements remains steady, ensuring a consistent market for Klor-Con M20.
- Regulatory and Market Dynamics: Changes in regulatory policies and market dynamics can significantly impact sales projections.
FAQs
What is Klor-Con M20 used for?
Klor-Con M20 is used to treat and prevent hypokalemia, a condition where the potassium levels in the blood are too low.
How does Klor-Con M20 differ from other potassium chloride supplements?
Klor-Con M20 is an extended-release oral dosage form containing microencapsulated potassium chloride, designed to slow the release of potassium and reduce the risk of high localized concentrations within the gastrointestinal tract.
What are the potential side effects of Klor-Con M20?
Potential side effects include severe vomiting, abdominal pain, distention, or gastrointestinal bleeding. It is contraindicated in patients with structural, pathological, or pharmacologic causes for arrest or delay in tablet passage through the gastrointestinal tract[1].
Is Klor-Con M20 available in generic form?
Yes, generic versions of potassium chloride are available, which can affect the pricing and market share of Klor-Con M20[4].
How does the pricing of Klor-Con M20 compare to its competitors?
The pricing of Klor-Con M20 is competitive, with costs ranging from $27.99 to $30.05 for different quantities, making it comparable to other extended-release potassium chloride products[4].
Sources
- DailyMed: KLOR-CON M- potassium chloride tablet, extended release.
- FTC: D:\Docket 9297 ScheringUpsher Initial Decision Final Redacted.
- ASPE: Antimicrobial Drugs Market Returns Analysis Final.
- Drugs.com: Klor-Con M20 Prices, Coupons, Copay Cards & Patient Assistance.
Last updated: 2024-12-31
